Home » Stocks » PTI

Proteostasis Therapeutics, Inc. (PTI)

Dec 23, 2020 - PTI merged into YMTX
Stock Price: $1.11 USD 0.00 (0.00%)
Updated Dec 22, 2021 4:00 PM EST
Market Cap 2.90M
Revenue (ttm) n/a
Net Income (ttm) -38.80M
Shares Out 52.18M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Dec 22, 2021
Last Price $1.11
Previous Close $1.11
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 1.10 - 1.20
Day's Volume 0
52-Week Range 0.89 - 2.44

News

Hide News
Benzinga - 3 weeks ago

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported results from the Phase 1 single ascending dose study in 40-healthy volunteers, evaluating its lead candidate, YTX-7739, an SCD inhibitor, for ...

Other stocks mentioned: YMTX
PRNewsWire - 2 months ago

BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections...

GlobeNewsWire - 2 months ago

Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus

PRNewsWire - 3 months ago

BOSTON, Nov. 16, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today announced financial results for the third quarter ended Se...

Zacks Investment Research - 3 months ago

Proteostasis Therapeutics (PTI) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 4 months ago

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, CWBR, DRRX, GRFS
Zacks Investment Research - 5 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ATO, CI, OTTR, THS
PRNewsWire - 5 months ago

PHILADELPHIA, Sept. 14, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Proteostasis Therapeutics, Inc.

GuruFocus - 6 months ago

A Boston-area biotech has found a nifty way to go public--by sneaking in the back door.

PRNewsWire - 6 months ago

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

Business Wire - 6 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRNewsWire - 6 months ago

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Proteostasis Therapeutics, Inc.

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Proteostasis Therapeutics, Inc. (NASDAQ: PTI) and its board of directors concerning the propo...

Newsfile Corp - 6 months ago

Wilmington, Delaware--(Newsfile Corp. - August 25, 2020) - Rigrodsky & Long, P.A.

PRNewsWire - 6 months ago

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Proteostasis Therapeutics, Inc.

Newsfile Corp - 6 months ago

New York, New York--(Newsfile Corp. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Proteostasis Therapeutics, Inc.

PRNewsWire - 6 months ago

BOSTON, Aug. 24, 2020 /PRNewswire/ -- Yumanity Therapeutics and Proteostasis Therapeutics, Inc.

Zacks Investment Research - 6 months ago

Proteostasis (PTI) delivered earnings and revenue surprises of 19.05% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 7 months ago

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Other stocks mentioned: AVGR, BLRX, VCNX, VIVE
PRNewsWire - 8 months ago

BOSTON, June 5, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ther...

PRNewsWire - 9 months ago

BOSTON, June 1, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking thera...

Seeking Alpha - 9 months ago

Proteostasis Therapeutics: A Clinical Stage Company That's Worth The Risk

Zacks Investment Research - 9 months ago

Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 9 months ago

BOSTON, May 15, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ther...

Zacks Investment Research - 9 months ago

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Other stocks mentioned: AVGR, FEYE, JAKK, WATT
Zacks Investment Research - 9 months ago

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.

Zacks Investment Research - 1 year ago

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

Other stocks mentioned: ABEO, APLT, EBF, ONTX
Zacks Investment Research - 1 year ago

Is (PTI) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Proteostasis Therapeutics

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Proteostasis (PTI) stock based on the movements in the options market lately.

The Motley Fool - 1 year ago

Positive clinical trial data wasn't positive enough.

24/7 Wall Street - 1 year ago

Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares were absolutely crushed on Tuesday after the firm announced midstage data from its cystic fibrosis (CF) study.

Market Watch - 1 year ago

Shares of Proteostasis Therapeutics Inc. PTI, +2.35% fell 35% in premarket trading on Tuesday after the biopharmaceutical company shared mixed findings from a mid-stage study for its experimen...

Seeking Alpha - 1 year ago

In the case of PTI and ACAD, their greater upside potential earlier this month won out.

Other stocks mentioned: ACAD
Zacks Investment Research - 1 year ago

Proteostasis Therapeutics (PTI) shares rose more than 7% in the last trading session, amid huge volumes.

24/7 Wall Street - 1 year ago

Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares jumped on Wednesday after the firm announced positive, initial ex-vivo results of its proprietary cystic fibrosis transmembrane conductance ...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Proteostasis Therapeutics, Inc. (PTI).

The Motley Fool - 1 year ago

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Other stocks mentioned: AGN, ALEC, AMRN, ATNX, BHVN, CARA, GBT, ITCI, NVS, PBYI, PTGX, RCKT
Zacks Investment Research - 1 year ago

Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Proteostasis Recruits Patients Quicker Than Anticipated, Results From CF Studies Now Expected Q4 2019

Zacks Investment Research - 1 year ago

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Proteostasis (PTI) delivered earnings and revenue surprises of -11.43% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.

Benzinga - 1 year ago

Micro-cap biotech Proteostasis Therapeutics Inc (NASDAQ: PTI) is strongly Tuesday morning.

Zacks Investment Research - 1 year ago

Proteostasis (PTI) delivered earnings and revenue surprises of 34.88% and 525.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.

Zacks Investment Research - 1 year ago

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

About PTI

Proteostasis Therapeutics, a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other p... [Read more...]

Industry
Biotechnology
IPO Date
Feb 11, 2016
CEO
Meenu Chhabra
Employees
44
Stock Exchange
NASDAQ
Ticker Symbol
PTI
Full Company Profile

Financial Performance

In 2019, PTI's revenue was $5.00 million, an increase of 76.06% compared to the previous year's $2.84 million. Losses were -$59.13 million, -4.38% less than in 2018.

Financial Statements